United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism Seite 1

24.04.2024 - COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH ... Seite 1

Related Keywords

Denmark ,United Kingdom ,Copenhagen ,Køavn ,Great Britain ,Ascendis Pharma ,Regulatory Agency ,Camilla Harder Harvig ,Executive Vice President ,Chief Commercial Officer ,Ascendis Pharma Chart ,Scendis Pharma Kurs ,Scendis Pharma Aktie ,